INTRODUCTION
"I invite you to explore the primary challenges and opportunities in research and development (R&D) within the medical device sector.
This analysis delves into the regulatory nuances and complexities of technological development, comparing approaches in key regions such as Europe, the United Kingdom, the United States, and Canada, and highlights regulatory strategies tailored to medical devices for rare diseases".
1. OVERVIEW OF R&D DEVELOPMENT FOR MEDICAL DEVICES
1.1. THE IMPORTANCE OF R&D IN MEDICAL DEVICES
The development of medical devices (MD) is marked by challenges, both technically and regulatory. Innovators must not only prove that their products are safe and effective but also navigate through a complex and constantly evolving regulatory landscape. Therefore, close collaboration between engineers, researchers, healthcare professionals, and regulatory advisors is essential to overcome these obstacles and succeed in bringing innovative medical devices to market.
1.2. PHASES OF R&D
R&D of medical devices typically unfolds in several distinct phases, each crucial to the success of the final product:
Preliminary design and development
Prototype development
Preclinical trials
Clinical trials
Authorization and marketing
Vigilance
2. THE REGULATORY FRAMEWORK FOR MEDICAL DEVICES
For the success of R&D in medical devices, it is crucial to understand the regulatory frameworks specific to different regions of the world, including Europe (as well as the national specificity of certain key countries), the United Kingdom, the United States, and Canada. This chapter aims to shed light on the diverse regulatory paths and highlight the particularities of each region.
2.1. EUROPE AND EUROPEAN COUNTRIES - General regulatory aspects:
Europe, with its new Medical Devices Regulation (MDR)[1], [2], has recently overhauled its regulatory approach, aiming to strengthen market surveillance and increase transparency for end-users.
This regulation introduces stricter requirements for clinical evaluation and post-market surveillance, placing a strong emphasis on patient safety [1], [2]. Meanwhile, the European Medicines Agency (EMA)[3] plays a crucial role in the evaluation and surveillance of medicines, though its impact on medical devices is more indirect.
Specificity
Classification of Medical Devices and control
Approval and Pre-marketing
Clinical Trial Authorization
Market Authorization
Post-market Surveillance
Existence of Regulatory Processes to Accelerate R&D in Rare Diseases
Table 1 : EUROPE AND EUROPEAN COUNTRIES - General regulatory aspects.
2.2. UNITED KINGDOM (MHRA) - General regulatory aspects:
With Brexit, the United Kingdom has taken a decisive turn, establishing its own regulatory framework for medical devices through the "Medicines and Healthcare products Regulatory Agency" (MHRA) [15], [16].
This new beginning promises to harmonize patient safety principles while promoting national innovation. The specifics introduced by the MHRA reflect a commitment to support research and development, navigating between the legacies of the European Union and a renewed British vision [15], [16].
Specificity
Classification of Medical Devices and control
Approval and Pre-marketing
Clinical Trial Authorization
Market Authorization
Post-market Surveillance
Existence of Regulatory Processes to Accelerate R&D in Rare Diseases
Table 2 : UNITED KINGDOM (MHRA) - General regulatory aspects
2.3. UNITED STATES (FDA) - General regulatory aspects:
In the United States, the Food and Drug Administration (FDA) guides medical devices to market [22]. Classified into three categories based on risk [23], Class I devices are subject to fewer constraints (510(k) notification) [23], [24], while Class III devices, essential for life support, undergo rigorous evaluation, including pre-market approval (PMA) [23], [25].
The clinical trial pathway is meticulously monitored by the FDA, starting with an Investigational Device Exemption (IDE) application [26], [27]. This step is crucial, providing necessary safety and efficacy data.
With its dual-path approval processes (510(k) and PMA), the FDA asserts its commitment to safety while fostering innovation. This strict regulatory and scientific framework ensures that medical devices introduced to the market are safe and effective, with the FDA overseeing each step, from design to post-market surveillance, setting a high standard for market access while also promoting innovation within the industry.
Specificity
Classification of Medical Devices and control
Approval and Pre-marketing
Clinical Trial Authorization
Market Authorization
Post-market Surveillance
Existence of Regulatory Processes to Accelerate R&D in Rare Diseases
Table 3 : UNITED STATES (FDA) - General Regulatory Aspects.
2.4. CANADA (HEALTH CANADA) - General regulatory aspects:
Canada is distinguished by its rigorous and innovative approach in the regulation of medical devices, overseen by Health Canada[33]. What makes it unique is its meticulous review process, notably through obtaining a Medical Device License (MDL) [34], which places a strong emphasis on quality and safety. This framework ensures that each medical device marketed meets high standards, thus guaranteeing efficacy and safety for users.
Innovation is at the heart of the Canadian system, with accelerated access pathways for technologies deemed essential, reflecting a perfect balance between scientific rigor and accessibility. This robust framework aims not only to protect public health but also to encourage innovation in the healthcare sector.
Specificity
Classification of Medical Devices and control
Approval and Pre-marketing
Clinical Trial Authorization
Market Authorization
Post-market Surveillance
Existence of Regulatory Processes to Accelerate R&D in Rare Diseases
Table 4 : CANADA (HEALTH CANADA) - General regulatory aspects
3. SUMMARY TABLE OF INTERNATIONAL MEDICAL DEVICE R&D
Table 5 : INTERNATIONAL MEDICAL DEVICE R&D - General Regulatory Aspects
HOPING THIS BRIEF SUMMARY HELPS YOU IN YOUR FUTURE PROJECTS IN R&D FOR MEDICAL DEVICES !
If you need help with your regulatory R&D for medical devices, feel free to contact me at contact@orphanquantum.com
See you soon,
Tristan.
*If I find more resources, I will add them to this list.
** Please let me know if you are aware of other rare disease resources that I may have missed and that could be relevant to include in this list.
SOURCES
[1] European parliament and the council of the european union, “REGULATION (EU) 2017/745 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL on medical devices.” Accessed: Feb. 13, 2024. [Online]. Available: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32017R0745
[2] “MDCG 2021-5 Guidance on standardisation for medical devices,” Medical Devices. Accessed: Feb. 13, 2024. [Online]. Available: https://health.ec.europa.eu/system/files/2021-04/md_mdcg_2021_5_en_0.pdf
[3] “Medical devices | European Medicines Agency.” Accessed: Feb. 12, 2024. [Online]. Available: https://www.ema.europa.eu/en/human-regulatory-overview/medical-devices
[4] “CE marking – obtaining the certificate, EU requirements,” Your Europe. Accessed: Feb. 13, 2024. [Online]. Available: https://europa.eu/youreurope/business/product-requirements/labels-markings/ce-marking/index_en.htm
[5] “Medical device classification.” Accessed: Feb. 13, 2024. [Online]. Available: https://webgate.ec.europa.eu/udi-helpdesk/en/other-relevant-information/medical-device-classification.html
[6] “Unique Device Identifier - UDI - European Commission.” Accessed: Feb. 13, 2024. [Online]. Available: https://health.ec.europa.eu/medical-devices-topics-interest/unique-device-identifier-udi_en
[7] A. M. Bruun, “CE Marking for Medical Devices [Step-by-Step Guide],” SimplerQMS. Accessed: Feb. 13, 2024. [Online]. Available: https://www.simplerqms.com/ce-marking-for-medical-devices/
[8] “Agence Nationale de la Sécurité du médicament,” ANSM. Accessed: Feb. 13, 2024. [Online]. Available: https://ansm.sante.fr/
[9] Deutsche Federal Institute for Drugs and Medical Devices, “BfArM - Homepage.” Accessed: Feb. 13, 2024. [Online]. Available: https://www.bfarm.de/EN/Home/_node.html
[10] “AEMPS - Agencia Española de Medicamentos y Productos Sanitarios,” Agencia Española de Medicamentos y Productos Sanitarios. Accessed: Feb. 13, 2024. [Online]. Available: https://www.aemps.gob.es/?lang=en/
[11] “AIFA - Italian Medicines Agency.” Accessed: Feb. 13, 2024. [Online]. Available: https://www.aifa.gov.it
[12] © Copyright Swissmedic 2019, “Swissmedic Homepage.” Accessed: Feb. 13, 2024. [Online]. Available: https://www.swissmedic.ch/swissmedic/en/home.html
[13] © Copyright Swissmedic 2019, “Regulation of medical devices.” Accessed: Feb. 13, 2024. [Online]. Available: https://www.swissmedic.ch/swissmedic/en/home/medizinprodukte/regulierung-medizinprodukte.html
[14] “EUDAMED database - EUDAMED.” Accessed: Feb. 13, 2024. [Online]. Available: https://ec.europa.eu/tools/eudamed/#/screen/home
[15] “MHRA - Medicines and Healthcare products Regulatory Agency,” GOV.UK. Accessed: Feb. 13, 2024. [Online]. Available: https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency
[16] “WITHDRAWAL OF THE UNITED KINGDOM AND EU RULES FOR MEDICINAL PRODUCTS FOR HUMAN USE AND VETERINARY MEDICINAL PRODUCTS.” Accessed: Feb. 13, 2024. [Online]. Available: https://commission.europa.eu/document/download/5512be00-565f-4c34-8cd6-c8691b137971_en?filename=notice_to_stakeholders_medicinal_products.pdf
[17] “MHRA - Regulating medical devices in the UK,” GOV.UK. Accessed: Feb. 13, 2024. [Online]. Available: https://www.gov.uk/guidance/regulating-medical-devices-in-the-uk
[18] “MHRA - Medical devices: conformity assessment and the UKCA mark,” GOV.UK. Accessed: Feb. 13, 2024. [Online]. Available: https://www.gov.uk/guidance/medical-devices-conformity-assessment-and-the-ukca-mark
[19] “MHRA - Medical Device Classification,” GOV.UK. Accessed: Feb. 13, 2024. [Online]. Available: https://www.gov.uk/government/consultations/consultation-on-the-future-regulation-of-medical-devices-in-the-united-kingdom/chapter-2-classification
[20] “Notify the MHRA about a clinical investigation for a medical device,” GOV.UK. Accessed: Feb. 13, 2024. [Online]. Available: https://www.gov.uk/guidance/notify-mhra-about-a-clinical-investigation-for-a-medical-device
[21] “MHRA - Medical devices: guidance for manufacturers on vigilance,” GOV.UK. Accessed: Feb. 13, 2024. [Online]. Available: https://www.gov.uk/government/collections/medical-devices-guidance-for-manufacturers-on-vigilance
[22] C. for D. and R. Health, “FDA - Medical Devices,” FDA. Accessed: Feb. 13, 2024. [Online]. Available: https://www.fda.gov/medical-devices
[23] C. for D. and R. Health, “FDA - Classify Your Medical Device,” FDA. Accessed: Feb. 13, 2024. [Online]. Available: https://www.fda.gov/medical-devices/overview-device-regulation/classify-your-medical-device
[24] C. for D. and R. Health, “FDA - Premarket Notification 510(k),” FDA. Accessed: Feb. 13, 2024. [Online]. Available: https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-notification-510k
[25] C. for D. and R. Health, “PMA - Premarket Approval (PMA),” FDA. Accessed: Feb. 13, 2024. [Online]. Available: https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/premarket-approval-pma
[26] C. for D. and R. Health, “FDA - Investigational Device Exemption (IDE),” FDA. Accessed: Feb. 13, 2024. [Online]. Available: https://www.fda.gov/medical-devices/premarket-submissions-selecting-and-preparing-correct-submission/investigational-device-exemption-ide
[27] C. for D. and R. Health, “FDA - How to Study and Market Your Device,” FDA. Accessed: Feb. 13, 2024. [Online]. Available: https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/how-study-and-market-your-device
[28] C. for D. and R. Health, “FDA - Postmarket Requirements (Devices),” FDA. Accessed: Feb. 13, 2024. [Online]. Available: https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/postmarket-requirements-devices
[29] “MAUDE - Manufacturer and User Facility Device Experience.” Accessed: Feb. 13, 2024. [Online]. Available: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfmaude/search.cfm
[30] C. for D. and R. Health, “FDA - Breakthrough Devices Program,” FDA, Sep. 2023, Accessed: Feb. 13, 2024. [Online]. Available: https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program
[31] O. of the Commissioner, “FDA - Humanitarian Use Device (HUD) Designation Program,” FDA. Accessed: Feb. 13, 2024. [Online]. Available: https://www.fda.gov/industry/medical-products-rare-diseases-and-conditions/humanitarian-use-device-hud-designation-program
[32] C. for D. and R. Health, “FDA - Humanitarian Device Exemption (HDE) Program.” Accessed: Feb. 13, 2024. [Online]. Available: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/humanitarian-device-exemption-hde-program
[33] H. Canada, “Health Canada - Medical devices.” Accessed: Feb. 13, 2024. [Online]. Available: https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices.html
[34] H. Canada, “Health Canada - Medical device licensing (MDL).” Accessed: Feb. 13, 2024. [Online]. Available: https://www.canada.ca/en/health-canada/services/licences-authorizations-registrations-drug-health-products/licence-authorization-registration-forms-drug-health-products/medical-device-licensing.html
[35] L. S. Branch, “Health Canada - Consolidated federal laws of Canada, Medical Devices Regulations - MD classification.” Accessed: Feb. 13, 2024. [Online]. Available: https://laws-lois.justice.gc.ca/eng/regulations/sor-98-282/page-2.html#h-1021414
[36] H. Canada, “Health Canada - Guidance on clinical evidence requirements for medical devices: Additional obligations during post-market phase.” Accessed: Feb. 13, 2024. [Online]. Available: https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/application-information/guidance-documents/clinical-evidence-requirements-medical-devices/additional-obligations-post-market-phase.html
[37] H. Canada, “Health Canada - Medical Device Establishment Licence (MDEL) application: instructions (FRM-0292).” Accessed: Feb. 13, 2024. [Online]. Available: https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/establishment-licences/forms/medical-device-establishment-licence-application-form-instructions-0292.html
[38] H. Canada, “Health Canada - Applications for Medical Device Investigational Testing Authorizations Guidance Document.” Accessed: Feb. 13, 2024. [Online]. Available: https://www.canada.ca/en/health-canada/services/drugs-health-products/medical-devices/application-information/guidance-documents/investigational-testing-authorizations-guidance/guidance-document.html
[39] H. Canada, “Health Canada - Incident reporting for medical devices: Guidance document.” Accessed: Feb. 13, 2024. [Online]. Available: https://www.canada.ca/en/health-canada/services/drugs-health-products/reports-publications/medeffect-canada/incident-reporting-medical-devices-guidance-2021.html
[40] H. Canada, “Health Canada - Health Canada’s special access programs: Request access to a medical device.” Accessed: Feb. 13, 2024. [Online]. Available: https://www.canada.ca/en/health-canada/services/drugs-health-products/special-access/medical-devices.html
Comments